NuVasive recent pullback a buying opportunity, says Piper Jaffray Piper Jaffray believes the impact of NuVasive's OIG subpoena will be minor and recommends using the recent pullback in shares as a buying opportunity. Piper said it would not be surprised to see a final settlement less than $10M and reiterates an Overweight rating on the stock with a $31 price target.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.